Form 4: Charles River Labs Exec Sells Shares

Shannon M. Parisotto, EVP of Discovery & Safety Assessment at Charles River Laboratories, reported transactions involving the sale of company stock.

Summary

• Shannon M. Parisotto, an executive at Charles River Laboratories (CRL), engaged in several stock transactions between May 29, 2026, and May 31, 2026.
• On May 29, 2026, Parisotto acquired 4,361 shares of common stock at a price of $180.71 per share.
• Subsequently, on May 30, 2026, Parisotto disposed of 551 shares at $180.71 per share.
• On May 31, 2026, an additional 170 shares were disposed of at the same price of $180.71 per share.
• Following these transactions, Parisotto beneficially owns 11,552 shares directly.
• Indirect beneficial ownership includes 8,151 shares held by Karpathos Investments LLC and an unspecified amount held by a trust.
• The filing also notes that unvested restricted stock units will vest annually on May 29, 2027, 2028, 2029, and 2030.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting routine insider transactions rather than significant company performance indicators.

Positives

• The executive acquired shares on May 29, 2026, indicating potential confidence or compensation.
• The majority of shares remain under beneficial ownership, both directly and indirectly.

Negatives

• The executive disposed of a net of 721 shares between May 30 and May 31, 2026.
• The disposal of shares could be interpreted as a signal of reduced confidence or a need for liquidity.

Risks

• The filing does not explicitly mention any risks or challenges.
• Potential future risks could include market volatility affecting the value of remaining holdings or the vesting of restricted stock units.

Future Outlook

Unvested restricted stock units are scheduled to vest annually through May 29, 2030, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported sales by Shannon M. Parisotto at Charles River Laboratories are typical for executives managing their compensation and personal portfolios, but any significant pattern of sales warrants monitoring by investors.

Stakeholder Impact

• Shareholders may observe the executive's stock sales, potentially influencing short-term trading sentiment.
• Employees may view these transactions as part of executive compensation and personal financial management.

Next Steps

• Continued vesting of restricted stock units through May 29, 2030.
• Monitoring of future insider transactions by Shannon M. Parisotto and other executives.

Key Dates

Keywords

Form 4, SEC Filing, Charles River Laboratories, CRL, Shannon M. Parisotto, Stock Transaction, Insider Trading, Beneficial Ownership, Restricted Stock Units, Executive Compensation